Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dendritic cell-based immunotherapy.

Literature DB >> 28025976

Dendritic cell-based immunotherapy.

Rachel L Sabado¹, Sreekumar Balan¹, Nina Bhardwaj¹.

Abstract

Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for harnessing the potential of a patient's own immune system to eliminate tumor cells in metastatic hormone-refractory cancer. Overall, although many DC vaccines have been tested in the clinic and proven to be immunogenic, and in some cases associated with clinical outcome, there remains no consensus on how to manufacture DC vaccines. In this review we will discuss what has been learned thus far about human DC biology from clinical studies, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity.

Entities: Disease Species

Mesh：

Substances：
Antigens, Neoplasm

Year: 2016 PMID： 28025976 PMCID： PMC5223236 DOI： 10.1038/cr.2016.157

Source DB: PubMed Journal: Cell Res ISSN： 1001-0602 Impact factor: 25.617

239 in total

1. Toll-like receptors control activation of adaptive immune responses.

Authors: M Schnare; G M Barton; A C Holt; K Takeda; S Akira; R Medzhitov
Journal: Nat Immunol Date: 2001-10 Impact factor: 25.606

2. Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific antitumor T cells.

Authors: Reza Mahdian; Parviz Kokhaei; Hossein Motieian Najar; Katja Derkow; Aniruddha Choudhury; Håkan Mellstedt
Journal: Med Oncol Date: 2006 Impact factor: 3.064

3. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

Authors: Dung T Le; Andrea Wang-Gillam; Vincent Picozzi; Tim F Greten; Todd Crocenzi; Gregory Springett; Michael Morse; Herbert Zeh; Deirdre Cohen; Robert L Fine; Beth Onners; Jennifer N Uram; Daniel A Laheru; Eric R Lutz; Sara Solt; Aimee Luck Murphy; Justin Skoble; Ed Lemmens; John Grous; Thomas Dubensky; Dirk G Brockstedt; Elizabeth M Jaffee
Journal: J Clin Oncol Date: 2015-01-12 Impact factor: 44.544

4. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.

Authors: Anupama Sharma; Ursula Koldovsky; Shuwen Xu; Rosemarie Mick; Robert Roses; Elizabeth Fitzpatrick; Susan Weinstein; Harvey Nisenbaum; Bruce L Levine; Kevin Fox; Paul Zhang; Gary Koski; Brian J Czerniecki
Journal: Cancer Date: 2012-01-17 Impact factor: 6.860

5. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Authors: Paola Filipazzi; Roberta Valenti; Veronica Huber; Lorenzo Pilla; Paola Canese; Manuela Iero; Chiara Castelli; Luigi Mariani; Giorgio Parmiani; Licia Rivoltini
Journal: J Clin Oncol Date: 2007-06-20 Impact factor: 44.544

6. Semi-allogeneic dendritic cells can induce antigen-specific T-cell activation, which is not enhanced by concurrent alloreactivity.

Authors: James W Wells; Chris J Cowled; David Darling; Barbara-Ann Guinn; Farzin Farzaneh; Alistair Noble; Joanna Galea-Lauri
Journal: Cancer Immunol Immunother Date: 2007-05-09 Impact factor: 6.968

Review 7. Spontaneous regression of metastases from melanoma: review of the literature.

Authors: Louise Vennegaard Kalialis; Krzysztof T Drzewiecki; Helle Klyver
Journal: Melanoma Res Date: 2009-10 Impact factor: 3.599

Review 8. Cancer immunotherapy with mRNA-transfected dendritic cells.

Authors: Eli Gilboa; Johannes Vieweg
Journal: Immunol Rev Date: 2004-06 Impact factor: 12.988

9. Human type 2 myeloid dendritic cells produce interferon-λ and amplify interferon-α in response to hepatitis C virus infection.

Authors: Shuye Zhang; Karen Kodys; Kui Li; Gyongyi Szabo
Journal: Gastroenterology Date: 2012-10-23 Impact factor: 22.682

10. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.

Authors: Lawrence Fong; Peter Carroll; Vivian Weinberg; Stephen Chan; Jera Lewis; John Corman; Christopher L Amling; Robert A Stephenson; Jeffrey Simko; Nadeem A Sheikh; Robert B Sims; Mark W Frohlich; Eric J Small
Journal: J Natl Cancer Inst Date: 2014-09-24 Impact factor: 13.506

173 in total

Review 1. Tumor-derived extracellular vesicles: molecular parcels that enable regulation of the immune response in cancer.

Authors: Colin Sheehan; Crislyn D'Souza-Schorey
Journal: J Cell Sci Date: 2019-10-15 Impact factor: 5.285

Review 2. Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines.

Authors: Mansi Saxena; Nina Bhardwaj
Journal: Curr Opin Immunol Date: 2017-07-18 Impact factor: 7.486

Review 3. Nano-engineered delivery systems for cancer imaging and therapy: Recent advances, future direction and patent evaluation.

Authors: Ghazal Nabil; Ketki Bhise; Samaresh Sau; Mohamed Atef; Hossny A El-Banna; Arun K Iyer
Journal: Drug Discov Today Date: 2018-08-16 Impact factor: 7.851

4. Towards superior dendritic-cell vaccines for cancer therapy.

Authors: Mansi Saxena; Sreekumar Balan; Vladimir Roudko; Nina Bhardwaj
Journal: Nat Biomed Eng Date: 2018-06-11 Impact factor: 25.671

Review 5. The interplay between cancer associated fibroblasts and immune cells in the context of radiation therapy.

Authors: Miles Piper; Adam C Mueller; Sana D Karam
Journal: Mol Carcinog Date: 2020-05-04 Impact factor: 4.784

Review 6. Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.

Authors: Samaresh Sau; Hashem O Alsaab; Ketki Bhise; Rami Alzhrani; Ghazal Nabil; Arun K Iyer
Journal: J Control Release Date: 2018-01-31 Impact factor: 9.776